$ARNI Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Arno Therapeutics, Inc.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Arno Therapeutics, Inc. Get notifications about new insider transactions in Arno Therapeutics, Inc for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jan 03 2017 | ARNI | Arno Therapeutics, ... | SUSSMAN S DONALD | Option Exercise | S | 1.75 | 1,383,702 | 2,421,479 | 0 | ||
Jan 03 2017 | ARNI | Arno Therapeutics, ... | SUSSMAN S DONALD | Option Exercise | S | 1.14 | 1,605,809 | 1,830,622 | 0 | ||
Jan 03 2017 | ARNI | Arno Therapeutics, ... | SUSSMAN S DONALD | Sell | S | 0.00 | 4,285,111 | 0 | 714,285 | 5 M to 714.3 K (-85.71 %) | |
Oct 05 2016 | ARNI | Arno Therapeutics, ... | TANEN DAVID M | Secretary | Option Exercise | P | 0.44 | 71,428 | 31,250 | 71,428 | |
Oct 05 2016 | ARNI | Arno Therapeutics, ... | TANEN DAVID M | Secretary | Buy | P | 0.00 | 142,857 | 0 | 314,569 | 171.7 K to 314.6 K (+83.20 %) |
Sep 08 2016 | ARNI | Arno Therapeutics, ... | SUSSMAN S DONALD | 10% Owner | Option Exercise | P | 0.44 | 357,142 | 156,250 | 357,142 | |
Sep 08 2016 | ARNI | Arno Therapeutics, ... | SUSSMAN S DONALD | 10% Owner | Buy | P | 0.00 | 714,285 | 0 | 714,285 | 0 to 714.3 K |
Aug 17 2016 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | P | 0.44 | 357,142 | 156,250 | 357,142 | |
Aug 17 2016 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Buy | P | 0.00 | 714,285 | 0 | 2,262,838 | 1.5 M to 2.3 M (+46.13 %) |
Aug 17 2016 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Option Exercise | P | 0.44 | 51,050 | 22,334 | 51,050 | |
Aug 17 2016 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Option Exercise | P | 0.44 | 131,508 | 57,535 | 131,508 | |
Aug 17 2016 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Option Exercise | P | 0.44 | 174,584 | 76,381 | 174,584 | |
Aug 17 2016 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Buy | P | 0.00 | 102,100 | 0 | 496,068 | 394 K to 496.1 K (+25.92 %) |
Aug 17 2016 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Buy | P | 0.00 | 263,017 | 0 | 1,277,905 | 1 M to 1.3 M (+25.92 %) |
Aug 17 2016 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Buy | P | 0.00 | 349,168 | 0 | 1,696,495 | 1.3 M to 1.7 M (+25.92 %) |
Apr 11 2016 | ARNI | Arno Therapeutics, ... | HAMILTON WILLIAM F PHD | Director | Option Exercise | A | 0.37 | 88,628 | 32,792 | 88,628 | |
Apr 11 2016 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | A | 0.37 | 177,256 | 65,585 | 177,256 | |
Apr 11 2016 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Buy | P | 0.35 | 206,986 | 72,445 | 393,968 | 187 K to 394 K (+110.70 %) |
Apr 11 2016 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Buy | P | 0.35 | 533,208 | 186,623 | 1,014,888 | 481.7 K to 1 M (+110.70 %) |
Apr 11 2016 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Buy | P | 0.35 | 707,868 | 247,754 | 1,347,327 | 639.5 K to 1.3 M (+110.70 %) |
Apr 11 2016 | ARNI | Arno Therapeutics, ... | Proniuk Stefan | Chief Development O ... | Option Exercise | A | 0.37 | 554,685 | 205,233 | 554,685 | |
Apr 11 2016 | ARNI | Arno Therapeutics, ... | Reizman Yacov | Director | Option Exercise | A | 0.37 | 88,628 | 32,792 | 88,628 | |
Apr 11 2016 | ARNI | Arno Therapeutics, ... | Ruchefsky Steven B | Director | Option Exercise | A | 0.37 | 88,628 | 32,792 | 88,628 | |
Apr 11 2016 | ARNI | Arno Therapeutics, ... | TANEN DAVID M | Secretary | Option Exercise | A | 0.37 | 88,628 | 32,792 | 88,628 | |
Apr 11 2016 | ARNI | Arno Therapeutics, ... | Zukiwski Alexander A | Chief Executive Off ... | Option Exercise | A | 0.37 | 1,196,070 | 442,546 | 1,196,070 | |
Jan 14 2016 | ARNI | Arno Therapeutics, ... | Ruchefsky Steven B | Director | Buy | P | 0.35 | 2,876,633 | 1,006,822 | 4,472,905 | 1.6 M to 4.5 M (+180.21 %) |
Jan 14 2016 | ARNI | Arno Therapeutics, ... | Zukiwski Alexander A | VP & Chief Medical ... | Buy | P | 0.35 | 144,806 | 50,682 | 261,832 | 117 K to 261.8 K (+123.74 %) |
Jan 14 2016 | ARNI | Arno Therapeutics, ... | TANEN DAVID M | Secretary | Buy | P | 0.35 | 362,015 | 126,705 | 362,015 | 0 to 362 K |
Jan 14 2016 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Buy | P | 0.35 | 714,285 | 250,000 | 858,094 | 143.8 K to 858.1 K (+496.69 %) |
Jan 14 2016 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Buy | P | 0.35 | 1,448,062 | 506,822 | 1,548,543 | 100.5 K to 1.5 M (+1,441.13 %) |
Jan 14 2016 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Buy | P | 0.35 | 206,986 | 72,445 | 393,968 | 187 K to 394 K (+110.70 %) |
Jan 14 2016 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Buy | P | 0.35 | 533,208 | 186,623 | 1,014,888 | 481.7 K to 1 M (+110.70 %) |
Jan 14 2016 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Buy | P | 0.35 | 707,868 | 247,754 | 1,347,327 | 639.5 K to 1.3 M (+110.70 %) |
Jan 14 2016 | ARNI | Arno Therapeutics, ... | Moorin Jay | Director | Option Exercise | A | 0.30 | 88,648 | 26,594 | 88,648 | |
Nov 06 2015 | ARNI | Arno Therapeutics, ... | Ruchefsky Steven B | Director | Option Exercise | A | 0.36 | 48,399 | 17,424 | 48,399 | |
Nov 06 2014 | ARNI | Arno Therapeutics, ... | Ruchefsky Steven B | Director | Option Exercise | A | 2.40 | 687,500 | 1,650,000 | 687,500 | |
Nov 06 2014 | ARNI | Arno Therapeutics, ... | Ruchefsky Steven B | Director | Option Exercise | D | 2.40 | 687,500 | 1,650,000 | 0 | |
Nov 06 2014 | ARNI | Arno Therapeutics, ... | Ruchefsky Steven B | Director | Option Exercise | A | 2.40 | 520,833 | 1,249,999 | 520,833 | |
Nov 06 2014 | ARNI | Arno Therapeutics, ... | Ruchefsky Steven B | Director | Option Exercise | D | 2.40 | 520,833 | 1,249,999 | 0 | |
Nov 06 2014 | ARNI | Arno Therapeutics, ... | Ruchefsky Steven B | Director | Option Exercise | A | 0.85 | 136,784 | 116,266 | 136,784 | |
Feb 26 2014 | ARNI | Arno Therapeutics, ... | KENYON LAWRENCE A | Chief Financial Off ... | Option Exercise | A | 2.23 | 223,445 | 498,282 | 223,445 | |
Jan 29 2014 | ARNI | Arno Therapeutics, ... | THURMAN RANDY H | Director | Option Exercise | A | 2.90 | 34,224 | 99,250 | 34,224 | |
Jan 28 2014 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | A | 2.90 | 68,448 | 198,499 | 68,448 | |
Jan 28 2014 | ARNI | Arno Therapeutics, ... | TANEN DAVID M | Secretary | Option Exercise | A | 2.90 | 34,224 | 99,250 | 34,224 | |
Jan 28 2014 | ARNI | Arno Therapeutics, ... | Ruchefsky Steven B | Director | Option Exercise | A | 2.90 | 34,224 | 99,250 | 34,224 | |
Jan 28 2014 | ARNI | Arno Therapeutics, ... | Reizman Yacov | Director | Option Exercise | A | 2.90 | 34,224 | 99,250 | 34,224 | |
Jan 28 2014 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Option Exercise | A | 2.90 | 34,224 | 99,250 | 34,224 | |
Jan 28 2014 | ARNI | Arno Therapeutics, ... | HAMILTON WILLIAM F PHD | Director | Option Exercise | A | 2.90 | 34,224 | 99,250 | 34,224 | |
Jan 28 2014 | ARNI | Arno Therapeutics, ... | Proniuk Stefan | VP of Product Devel ... | Option Exercise | A | 2.90 | 171,877 | 498,443 | 171,877 | |
Jan 28 2014 | ARNI | Arno Therapeutics, ... | Zukiwski Alexander A | VP & Chief Medical ... | Option Exercise | A | 2.90 | 711,301 | 2,062,773 | 711,301 | |
Jan 28 2014 | ARNI | Arno Therapeutics, ... | Navins Scott L | Treasurer | Option Exercise | A | 2.90 | 125,457 | 363,825 | 125,457 | |
Jan 28 2014 | ARNI | Arno Therapeutics, ... | Mattes Glenn R. | President & CEO | Option Exercise | A | 2.90 | 408,892 | 1,185,787 | 408,892 | |
Nov 08 2013 | ARNI | Arno Therapeutics, ... | Zukiwski Alexander A | VP & Chief Medical ... | Option Exercise | A | 2.40 | 316,389 | 759,334 | 316,389 | |
Nov 06 2013 | ARNI | Arno Therapeutics, ... | THURMAN RANDY H | Director | Option Exercise | A | 2.40 | 68,448 | 164,275 | 68,448 | |
Nov 06 2013 | ARNI | Arno Therapeutics, ... | Mattes Glenn R. | President & CEO | Option Exercise | A | 2.40 | 386,697 | 928,073 | 386,697 | |
Nov 06 2013 | ARNI | Arno Therapeutics, ... | TANEN DAVID M | Secretary | Option Exercise | A | 2.40 | 68,448 | 164,275 | 68,448 | |
Nov 06 2013 | ARNI | Arno Therapeutics, ... | Ruchefsky Steven B | Director | Option Exercise | A | 2.40 | 205,344 | 492,826 | 205,344 | |
Nov 06 2013 | ARNI | Arno Therapeutics, ... | Proniuk Stefan | VP of Product Devel ... | Option Exercise | A | 2.40 | 45,701 | 109,682 | 45,701 | |
Nov 06 2013 | ARNI | Arno Therapeutics, ... | Reizman Yacov | Director | Option Exercise | A | 2.40 | 68,448 | 164,275 | 68,448 | |
Nov 06 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Option Exercise | A | 2.40 | 68,448 | 164,275 | 68,448 | |
Nov 06 2013 | ARNI | Arno Therapeutics, ... | HAMILTON WILLIAM F PHD | Director | Option Exercise | A | 2.40 | 68,448 | 164,275 | 68,448 | |
Nov 06 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | A | 2.40 | 3,559,296 | 8,542,310 | 3,559,296 | |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | A | 2.40 | 83,333 | 199,999 | 83,333 | |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | D | 2.40 | 83,333 | 199,999 | 0 | |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | C | 2.40 | 83,333 | 199,999 | 0 | |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | P | 2.40 | 83,333 | 199,999 | 83,333 | |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | P | 4.00 | 83,333 | 333,332 | 83,333 | |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | A | 2.40 | 62,500 | 150,000 | 62,500 | |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | D | 2.40 | 62,500 | 150,000 | 0 | |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | C | 2.40 | 62,500 | 150,000 | 0 | |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Grant | A | 2.40 | 6,666 | 15,998 | 100,481 | 93.8 K to 100.5 K (+7.11 %) |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Buy | C | 2.40 | 88,871 | 213,290 | 93,815 | 4.9 K to 93.8 K (+1,797.55 %) |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Buy | P | 0.00 | 83,332 | 0 | 174,644 | 91.3 K to 174.6 K (+91.26 %) |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Grant | A | 2.40 | 5,000 | 12,000 | 91,312 | 86.3 K to 91.3 K (+5.79 %) |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Buy | C | 2.40 | 66,652 | 159,965 | 86,312 | 19.7 K to 86.3 K (+339.02 %) |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | P | 2.40 | 187,500 | 450,000 | 187,500 | |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | P | 4.00 | 187,500 | 750,000 | 187,500 | |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | A | 2.40 | 145,833 | 349,999 | 145,833 | |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | D | 2.40 | 145,833 | 349,999 | 0 | |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | C | 2.40 | 145,833 | 349,999 | 0 | |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | P | 2.40 | 104,166 | 249,998 | 104,166 | |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | P | 4.00 | 104,166 | 416,664 | 104,166 | |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | A | 2.40 | 125,000 | 300,000 | 125,000 | |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | D | 2.40 | 125,000 | 300,000 | 0 | |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | C | 2.40 | 125,000 | 300,000 | 0 | |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | P | 2.40 | 104,166 | 249,998 | 104,166 | |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | P | 4.00 | 104,166 | 416,664 | 104,166 | |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Buy | P | 0.00 | 187,500 | 0 | 379,294 | 191.8 K to 379.3 K (+97.76 %) |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Grant | A | 2.40 | 11,666 | 27,998 | 191,794 | 180.1 K to 191.8 K (+6.48 %) |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Buy | C | 2.40 | 155,523 | 373,255 | 180,128 | 24.6 K to 180.1 K (+632.08 %) |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Buy | P | 0.00 | 104,166 | 0 | 254,887 | 150.7 K to 254.9 K (+69.11 %) |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Grant | A | 2.40 | 10,000 | 24,000 | 150,721 | 140.7 K to 150.7 K (+7.11 %) |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Buy | C | 2.40 | 133,305 | 319,932 | 140,721 | 7.4 K to 140.7 K (+1,797.53 %) |
Nov 05 2013 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Buy | P | 0.00 | 104,166 | 0 | 143,809 | 39.6 K to 143.8 K (+262.76 %) |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Zukiwski Alexander A | VP & Chief Medical ... | Option Exercise | P | 2.40 | 41,666 | 99,998 | 41,666 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Zukiwski Alexander A | VP & Chief Medical ... | Option Exercise | P | 4.00 | 41,666 | 166,664 | 41,666 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Zukiwski Alexander A | VP & Chief Medical ... | Option Exercise | A | 2.40 | 62,500 | 150,000 | 62,500 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Zukiwski Alexander A | VP & Chief Medical ... | Option Exercise | D | 2.40 | 62,500 | 150,000 | 0 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Zukiwski Alexander A | VP & Chief Medical ... | Option Exercise | C | 2.40 | 62,500 | 150,000 | 0 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Zukiwski Alexander A | VP & Chief Medical ... | Buy | P | 0.00 | 41,666 | 0 | 117,026 | 75.4 K to 117 K (+55.29 %) |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Zukiwski Alexander A | VP & Chief Medical ... | Grant | A | 2.40 | 5,000 | 12,000 | 75,360 | 70.4 K to 75.4 K (+7.11 %) |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Zukiwski Alexander A | VP & Chief Medical ... | Buy | C | 2.40 | 66,652 | 159,965 | 70,360 | 3.7 K to 70.4 K (+1,797.52 %) |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | HAMILTON WILLIAM F PHD | Director | Option Exercise | P | 2.40 | 20,833 | 49,999 | 20,833 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | HAMILTON WILLIAM F PHD | Director | Option Exercise | P | 4.00 | 20,833 | 83,332 | 20,833 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | HAMILTON WILLIAM F PHD | Director | Buy | P | 0.00 | 20,833 | 0 | 22,079 | 1.2 K to 22.1 K (+1,671.99 %) |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Proniuk Stefan | VP of Product Devel ... | Option Exercise | A | 2.40 | 8,333 | 19,999 | 8,333 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Proniuk Stefan | VP of Product Devel ... | Option Exercise | D | 2.40 | 8,333 | 19,999 | 0 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Proniuk Stefan | VP of Product Devel ... | Option Exercise | C | 2.40 | 8,333 | 19,999 | 0 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Proniuk Stefan | VP of Product Devel ... | Grant | A | 2.40 | 666 | 1,598 | 10,047 | 9.4 K to 10 K (+7.10 %) |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Proniuk Stefan | VP of Product Devel ... | Buy | C | 2.40 | 8,887 | 21,329 | 9,381 | 494 to 9.4 K (+1,798.99 %) |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Ruchefsky Steven B | Director | Option Exercise | P | 2.40 | 687,500 | 1,650,000 | 687,500 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Ruchefsky Steven B | Director | Option Exercise | P | 4.00 | 687,500 | 2,750,000 | 687,500 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Ruchefsky Steven B | Director | Option Exercise | A | 2.40 | 520,833 | 1,249,999 | 520,833 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Ruchefsky Steven B | Director | Option Exercise | D | 2.40 | 520,833 | 1,249,999 | 0 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Ruchefsky Steven B | Director | Option Exercise | C | 2.40 | 520,833 | 1,249,999 | 0 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Ruchefsky Steven B | Director | Grant | A | 2.40 | 41,666 | 99,998 | 1,596,272 | 1.6 M to 1.6 M (+2.68 %) |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Ruchefsky Steven B | Director | Buy | P | 0.00 | 687,500 | 0 | 1,554,606 | 867.1 K to 1.6 M (+79.29 %) |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Ruchefsky Steven B | Director | Buy | C | 2.40 | 555,440 | 1,333,056 | 867,106 | 311.7 K to 867.1 K (+178.22 %) |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Mattes Glenn R. | President & CEO | Option Exercise | P | 2.40 | 20,833 | 49,999 | 20,833 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Mattes Glenn R. | President & CEO | Option Exercise | P | 4.00 | 20,833 | 83,332 | 20,833 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Mattes Glenn R. | President & CEO | Option Exercise | A | 2.40 | 20,833 | 49,999 | 20,833 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Mattes Glenn R. | President & CEO | Option Exercise | D | 2.40 | 20,833 | 49,999 | 0 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Mattes Glenn R. | President & CEO | Option Exercise | C | 2.40 | 20,833 | 49,999 | 0 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Mattes Glenn R. | President & CEO | Buy | P | 0.00 | 20,833 | 0 | 77,203 | 56.4 K to 77.2 K (+36.96 %) |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Mattes Glenn R. | President & CEO | Grant | A | 2.40 | 1,666 | 3,998 | 56,370 | 54.7 K to 56.4 K (+3.05 %) |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Mattes Glenn R. | President & CEO | Buy | C | 2.40 | 22,218 | 53,323 | 54,704 | 32.5 K to 54.7 K (+68.39 %) |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Option Exercise | P | 2.40 | 59,558 | 142,939 | 59,558 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Option Exercise | P | 2.40 | 59,558 | 142,939 | 59,558 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Option Exercise | A | 2.40 | 59,558 | 142,939 | 59,558 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Option Exercise | D | 2.40 | 59,558 | 142,939 | 0 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Option Exercise | C | 2.40 | 59,558 | 142,939 | 0 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Option Exercise | P | 2.40 | 153,426 | 368,222 | 153,426 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Option Exercise | P | 2.40 | 153,426 | 368,222 | 153,426 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Option Exercise | A | 2.40 | 153,426 | 368,222 | 153,426 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Option Exercise | D | 2.40 | 153,426 | 368,222 | 0 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Option Exercise | C | 2.40 | 153,426 | 368,222 | 0 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Option Exercise | P | 2.40 | 203,682 | 488,837 | 203,682 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Option Exercise | P | 2.40 | 203,682 | 488,837 | 203,682 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Option Exercise | A | 2.40 | 203,682 | 488,837 | 203,682 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Option Exercise | D | 2.40 | 203,682 | 488,837 | 0 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Option Exercise | C | 2.40 | 203,682 | 488,837 | 0 | |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Buy | P | 0.00 | 59,558 | 0 | 186,982 | 127.4 K to 187 K (+46.74 %) |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Grant | A | 2.40 | 4,764 | 11,434 | 127,424 | 122.7 K to 127.4 K (+3.88 %) |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Buy | C | 2.40 | 63,516 | 152,438 | 122,660 | 59.1 K to 122.7 K (+107.39 %) |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Buy | P | 0.00 | 153,426 | 0 | 481,680 | 328.3 K to 481.7 K (+46.74 %) |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Grant | A | 2.40 | 12,274 | 29,458 | 328,254 | 316 K to 328.3 K (+3.88 %) |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Buy | C | 2.40 | 163,620 | 392,688 | 315,980 | 152.4 K to 316 K (+107.39 %) |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Buy | P | 0.00 | 203,682 | 0 | 639,459 | 435.8 K to 639.5 K (+46.74 %) |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Grant | A | 2.40 | 16,294 | 39,106 | 435,777 | 419.5 K to 435.8 K (+3.88 %) |
Oct 31 2013 | ARNI | Arno Therapeutics, ... | Kariv Tomer | Director | Buy | C | 2.40 | 217,216 | 521,318 | 419,483 | 202.3 K to 419.5 K (+107.39 %) |